13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Importance of Type I and III Interferons at Respiratory and Intestinal Barrier Surfaces

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Interferons (IFNs) constitute the first line of defense against microbial infections particularly against viruses. They provide antiviral properties to cells by inducing the expression of hundreds of genes known as interferon-stimulated genes (ISGs). The two most important IFNs that can be produced by virtually all cells in the body during intrinsic innate immune response belong to two distinct families: the type I and type III IFNs. The type I IFN receptor is ubiquitously expressed whereas the type III IFN receptor’s expression is limited to epithelial cells and a subset of immune cells. While originally considered to be redundant, type III IFNs have now been shown to play a unique role in protecting mucosal surfaces against pathogen challenges. The mucosal specific functions of type III IFN do not solely rely on the restricted epithelial expression of its receptor but also on the distinct means by which type III IFN mediates its anti-pathogen functions compared to the type I IFN. In this review we first provide a general overview on IFNs and present the similarities and differences in the signal transduction pathways leading to the expression of either type I or type III IFNs. By highlighting the current state-of-knowledge of the two archetypical mucosal surfaces ( e.g. the respiratory and intestinal epitheliums), we present the differences in the signaling cascades used by type I and type III IFNs to uniquely induce the expression of ISGs. We then discuss in detail the role of each IFN in controlling pathogen infections in intestinal and respiratory epithelial cells. Finally, we provide our perspective on novel concepts in the field of IFN (stochasticity, response heterogeneity, cellular polarization/differentiation and tissue microenvironment) that we believe have implications in driving the differences between type I and III IFNs and could explain the preferences for type III IFNs at mucosal surfaces.

          Related collections

          Most cited references119

          • Record: found
          • Abstract: found
          • Article: not found

          IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

          We report here the identification of a ligand-receptor system that, upon engagement, leads to the establishment of an antiviral state. Three closely positioned genes on human chromosome 19 encode distinct but paralogous proteins, which we designate interferon-lambda1 (IFN-lambda1), IFN-lambda2 and IFN-lambda3 (tentatively designated as IL-29, IL-28A and IL-28B, respectively, by HUGO). The expression of IFN-lambda mRNAs was inducible by viral infection in several cell lines. We identified a distinct receptor complex that is utilized by all three IFN-lambda proteins for signaling and is composed of two subunits, a receptor designated CRF2-12 (also designated as IFN-lambdaR1) and a second subunit, CRF2-4 (also known as IL-10R2). Both receptor chains are constitutively expressed on a wide variety of human cell lines and tissues and signal through the Jak-STAT (Janus kinases-signal transducers and activators of transcription) pathway. This receptor-ligand system may contribute to antiviral or other defenses by a mechanism similar to, but independent of, type I IFNs.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            IL-28, IL-29 and their class II cytokine receptor IL-28R.

            Cytokines play a critical role in modulating the innate and adaptive immune systems. Here, we have identified from the human genomic sequence a family of three cytokines, designated interleukin 28A (IL-28A), IL-28B and IL-29, that are distantly related to type I interferons (IFNs) and the IL-10 family. We found that like type I IFNs, IL-28 and IL-29 were induced by viral infection and showed antiviral activity. However, IL-28 and IL-29 interacted with a heterodimeric class II cytokine receptor that consisted of IL-10 receptor beta (IL-10Rbeta) and an orphan class II receptor chain, designated IL-28Ralpha. This newly described cytokine family may serve as an alternative to type I IFNs in providing immunity to viral infection.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Shared and Distinct Functions of Type I and Type III Interferons

              Type I interferons (IFNs) (IFN-α, IFN-β) and type III IFNs (IFN-λ) share many properties, including induction by viral infection, activation of shared signaling pathways, and transcriptional programs. However, recent discoveries have revealed context-specific functional differences. Here, we provide a comprehensive review of type I and type III IFN activities, highlighting shared and distinct features from molecular mechanisms through physiological responses. Beyond discussing canonical antiviral functions, we consider the adaptive immune priming, anti-tumor, and autoimmune functions of IFNs. We discuss a model wherein type III IFNs serve as a front-line defense that controls infection at epithelial barriers while minimizing damaging inflammatory responses, reserving the more potent type I IFN response for when local responses are insufficient. In this context, we discuss current therapeutic applications targeting these cytokine pathways and highlight gaps in understanding of the biology of type I and type III IFNs in health and disease.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                11 December 2020
                2020
                : 11
                : 608645
                Affiliations
                [1] 1 Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital , Heidelberg, Germany
                [2] 2 Department of Infectious Diseases, Virology, Heidelberg University Hospital , Heidelberg, Germany
                [3] 3 Research Group “Cellular polarity and viral infection”, German Cancer Research Center (DKFZ) , Heidelberg, Germany
                Author notes

                Edited by: Mark R. Walter, University of Alabama at Birmingham, United States

                Reviewed by: Raymond P. Donnelly, United States Food and Drug Administration, United States; Alessandra Pierangeli, Sapienza University of Rome, Italy

                *Correspondence: Megan L. Stanifer, m.stanifer@ 123456dkfz.de ; Steeve Boulant, s.boulant@ 123456dkfz.de

                †These authors have contributed equally to this work

                This article was submitted to Cytokines and Soluble Mediators in Immunity, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2020.608645
                7759678
                33362795
                73e97e8f-849f-4768-affc-9d18009bc06c
                Copyright © 2020 Stanifer, Guo, Doldan and Boulant

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 21 September 2020
                : 11 November 2020
                Page count
                Figures: 3, Tables: 2, Equations: 0, References: 120, Pages: 14, Words: 8437
                Funding
                Funded by: Deutsche Forschungsgemeinschaft 10.13039/501100001659
                Funded by: Deutsche Forschungsgemeinschaft 10.13039/501100001659
                Funded by: Deutsche Forschungsgemeinschaft 10.13039/501100001659
                Funded by: Deutsche Forschungsgemeinschaft 10.13039/501100001659
                Funded by: Deutsche Forschungsgemeinschaft 10.13039/501100001659
                Funded by: Deutscher Akademischer Austauschdienst 10.13039/501100001655
                Funded by: China Scholarship Council 10.13039/501100004543
                Categories
                Immunology
                Review

                Immunology
                interferons,type i interferon,type iii interferon,interferon lambda,mucosal immunity,epithelial cells,respiratory epithelia,intestinal epithelium

                Comments

                Comment on this article